06/30/22 6:45 AMNYSE : PFE Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™Pfizer Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for approval of PAXLOVID™ for patients who are at high risk for progression to severe illness from COVID-19. PAXLOVID is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with...RHEA-AIneutral
06/29/22 4:45 PMNYSE, Nasdaq : PFE, BNTX covid-19Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 VaccinePfizer Inc. and BioNTech SE today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses. “As the virus evolves, this new agreement will help ensure people across the country have access to vaccines that may...RHEA-AIneutral
06/28/22 6:00 AMNYSE, Nasdaq : PFE, ROIV Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and LupusRoivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in September 2021 through a transaction between Roivant and Pfizer, in which Pfizer licensed oral and topical...RHEA-AIneutral
06/25/22 10:00 AMNYSE, Nasdaq : PFE, BNTX covid-19Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against OmicronPfizer Inc. and BioNTech SE today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1...RHEA-AIneutral
06/24/22 10:00 AMNYSE : PFE conferencesPfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with AnalystsPfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Thursday, July 28, 2022. About Pfizer: Breakthroughs That Change Patients’ Lives. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.RHEA-AIneutral
06/23/22 10:35 AMNYSE : PFE dividendsPfizer Declares Third-Quarter 2022 DividendPfizer Inc. today announced that its board of directors declared a $0.40 third-quarter 2022 dividend on the company’ s common stock, payable September 6, 2022, to holders of the Common Stock of record at the close of business on July 29, 2022. The third-quarter 2022 cash dividend will be the 335th consecutive quarterly dividend paid by Pfizer.RHEA-AIneutral
06/20/22 1:00 AMNYSE, Nasdaq : PFE, VALN Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15Valneva SE, a specialty vaccine company, and Pfizer Inc. today announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease...RHEA-AIpositive
06/17/22 9:24 AMNYSE, Nasdaq : PFE, BNTX covid-19Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of AgePfizer Inc. and BioNTech SE today announced the U.S. Food and Drug Administration granted emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine as a three 3- µg dose series for children 6 months through 4 years of age. We know many parents in the U.S. have been eagerly awaiting an authorized vaccine for their children...RHEA-AIpositive
06/14/22 4:30 PMNYSE : PFE Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDAPfizer Inc. today shared data from the Phase 2/ 3 EPIC-SR study evaluating the use of PAXLOVID™ in patients who are at standard risk for developing severe COVID-19. “Results from our Phase 2/ 3 EPIC-HR and EPIC-SR studies, as well as post-authorization experience, support the efficacy and safety profile for PAXLOVID in the treatment of mild-to-moderate COVID-19...RHEA-AInegative
06/13/22 4:01 PMNasdaq : MOR, PFE, INCY clinical trialPfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47Pfizer Inc., MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG, and Incyte today announced a clinical trial collaboration and supply agreement to investigate the immunotherapeutic combination of Pfizer’ s TTI-622, a novel SIRPα-Fc fusion protein, and Monjuvi ® plus lenalidomide in patients with relapsed or...RHEA-AIpositive
